GOSS (Gossamer Bio) Dividends per Share : $0.00 (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Dividends per Share?

Gossamer Bio's dividends per share for the three months ended in Sep. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Gossamer Bio's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Gossamer Bio Dividends per Share Historical Data

The historical data trend for Gossamer Bio's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Dividends per Share Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Gossamer Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Gossamer Bio's Dividends per Share

For the Biotechnology subindustry, Gossamer Bio's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gossamer Bio's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Dividend Yield % falls into.

Gossamer Bio Dividends per Share Calculation

Dividends paid to per common share.

Gossamer Bio (NAS:GOSS) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Gossamer Bio's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.14
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Gossamer Bio Dividends per Share Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Executives

Richard Aranda	officer: Chief Medical Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain	director, officer: Executive Chairman	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Bryan Giraudo	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Waage Christian	officer: EVP & General Counsel	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson	officer: EVP, Regulatory Affairs	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Sandra Milligan	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Laura Carter	officer: Chief Scientific Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid	officer: Chief Scientific Officer	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont	officer: Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi	director, officer: President & CEO	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox	director	C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2